Substance P and its receptors - A potential target for novel medicines in malignant brain tumour therapies (mini-review)

Folia Neuropathologica

Volumn 45, Issue 3, 2007, Pages 99-107

  Łazarczyk, Marzena ^a   Matyja, Ewa ^a   Lipkowski, Andrzej ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Glioma malignancy; NK1 tachykinin receptor; Substance P

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; ANTIEMETIC AGENT; APREPITANT; CISPLATIN; CYTOKINE; DNA; G PROTEIN COUPLED RECEPTOR; GR 71251; L 754 030; MEN 10581; MEN 11467; MITOGEN ACTIVATED PROTEIN KINASE; N ACETYLTRYPTOPHAN 3,5 BIS(TRIFLUOROMETHYL)BENZYL ESTER; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NEPADUTANT; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR; NEUROKININ 2 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR; NEUROPEPTIDE; NOLPITANTIUM; SUBSTANCE P; SUBSTANCE P ANTAGONIST; SUBSTANCE P RECEPTOR; TACHYKININ DERIVATIVE; TACHYKININ RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; BRAIN NERVE CELL; BRAIN TUMOR; CANCER INHIBITION; CARCINOGENESIS; CELL DIVISION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CHEMOTHERAPY INDUCED EMESIS; DNA SYNTHESIS; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME ACTIVATION; GLIA CELL; GLIOMA; HUMAN; IMMUNOMODULATION; NEUROPATHOLOGY; NOCICEPTION; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; POSTOPERATIVE PAIN; PROTEIN FAMILY; PROTEIN SYNTHESIS; SHORT SURVEY; STOMACH IRRITATION; SYNAPTIC TRANSMISSION;

EID: 34948856407     PISSN: 16414640     EISSN: 1509572X     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (65)

1. Andrews PL, Kovacs M, Watson JW. The anti-emetic action of the neurokinin(1) receptor antagonist CP-99,994 does not require the presence of the area postrema in the dog. Neurosci Lett 2001; 314: 102-104.
2. Berger A, Paige CJ. Hemokinin-1 has Substance P-like function in U-251 MG astrocytoma cells: a pharmacological and functional study. J Neuroimmunol 2005; 164: 48-56.
3. Bettinger I, Thanos S, Paulus W. Microglia promote glioma migration. Acta Neuropathol (Berl) 2002; 103: 351-355.
4. Bigioni M, Benzo A, Irrissuto C, Maggi CA, Goso C. Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs 2005; 16: 1083-1089.
5. Bilkei-Gorzo A, Zimmer A. Mutagenesis and knockout models: NK1 and substance P. Handb Exp Pharmacol 2005; 169: 143-162.
6. Binder W, Scott C, Walker JS. Involvement of substance P in the anti-inflammatory effects of the peripherally selective kappa-opioid asimadoline and the NK1 antagonist GR205171. Eur J Neurosci 1999; 11: 2065-2072.
7. Hu CP, Feng JT, Tang YL, Zhu JQ, Lin MJ, Yu ME. LIF upregulates expression of NK-1R in NHBE cells. Mediators Inflamm 2006; Article ID 84829, pp. 1-8.
8. Cottrell GS, Padilla B, Pikios S, Roosterman D, Steinhoff M, Gehringer D, Grady EF, Bunnett NW. Ubiquitin-dependent down-regulation of the neurokinin-1 receptor. J Biol Chem 2006; 281: 27773-27783.
9. Delgado AV, McManus AT, Chambers JP. Exogenous administration of Substance P enhances wound healing in a novel skin-injury model. Exp Biol Med (Maywood) 2005; 230: 271-280.
10. Deschepper CF. Peptide receptors on astrocytes. Front Neuroendocrinol 1998; 19: 20-46.
11. Dionne RA, Max MB, Gordon SM, Parada S, Sang C, Gracely RH, Sethna NF, MacLean DB. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin Pharmacol Ther 1998; 64: 562-568.
12. Di Sebastiano P, Grossi L, Di Mola FF, Angelucci D, Friess H, Marzio L, Innocenti P, Buchler MW. SR140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis. Dig Dis Sci 1999; 44: 439-444.
13. Dunlop RJ, Campbell CW. Cytokines and advanced cancer. J Pain Symptom Manage 2000; 20: 214-232.
14. Esteban F, Munoz M, Gonzalez-Moles MA, Rosso M. A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev 2006; 25: 137-145.
15. Ferreira J, Triches KM, Medeiros R, Calixto JB. Mechanisms involved in the nociception produced by peripheral protein kinase c activation in mice. Pain 2005; 117: 171-181.
16. Galiano M, Gasparre G, Lippe C, Cassano G. Calcium response after stimulation by substance P of U373 MG cells: inhibition of store-operated calcium entry by protein kinase C. Cell Calcium 2004; 35: 123-130.
17. Garret C, Carruette A, Fardin V, Moussaoui S, Peyronel JF, Blanchard JC, Laduron PM. RP 67580, a potent and selective substance P non-peptide antagonist. C R Acad Sci III 1992; 314: 199-204.
18. Girish C, Manikandan S. Aprepitant: a substance P antagonist for chemotherapy induced nausea and vomiting. Indian J Cancer 2007; 44: 25-30.
19. Guo CJ, Douglas SD, Gao Z, Wolf BA, Grinspan J, Lai JP, Riedel E, Ho WZ. Interleukin-1beta upregulates functional expression of neurokinin-1 receptor (NK-1R) via NF-kappaB in astrocytes. Glia 2004; 48: 259-266.
20. Harrison S, Geppetti P. Substance P. Int J Biochem Cell Biol 2001; 33: 555-576.
21. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 1995; 61: 786-792.
22. Hu CP, Feng JT, Tang YL, Zhu JQ, Lin MJ, Yu ME. LIF upregulates expression of NK1R in NHBE cells. Mediators Inflamm 2006; 5: 84829-84831.
23. Hu DE, Hori Y, Fan TP. Interleukin-8 stimulates angiogenesis in rats. Inflammation 1993; 17: 135-143.
24. Jenkinson KM, Southwell BR, Furness JB. Two affinities for a single antagonist at the neuronal NK1 tachykinin receptor: evidence from quantitation of receptor endocytosis. Br J Pharmacol 1999; 126: 131-136.
25. Jennings MT, Pietenpol JA. The role of transforming growth factor beta in glioma progression. J Neurooncol 1998; 36: 123-140.
26. Kan KK, Rudd JA, Wai MK. Differential action of anti-emetic drugs on defecation and emesis induced by prostaglandin E2 in the ferret. Eur J Pharmacol 2006; 544: 153-159.
27. Kettenmann H, Ransom BR (eds.). Neuroglia. 2nd ed. Oxford University Press 2005.
28. Khawaja AM, Rogers DF. Tachykinins: receptor to effector. Int J Biochem Cell Biol 1996; 28: 721-738.
29. Lai JP, Douglas SD, Wang YJ, Ho WZ. Real-time reverse transcription-PCR quantitation of substance P receptor (NK-1R) mRNA. Clin Diagn Lab Immunol 2005; 12: 537-541.
30. Lieb K, Fiebich BL, Berger M, Bauer J, Schulze-Osthoff K. The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol 1997; 159: 4952-4958.
31. Martin FC, Charles AC, Sanderson MJ, Merrill JE. Substance P stimulates IL-1 production by astrocytes via intracellular calcium. Brain Res 1992; 599: 13-18.
32. Morbidelli L, Maggi CA, Ziche M. Effect of selective tachykinin receptor antagonists on the growth of human skin fibroblasts. Neuropeptides 1993; 24: 335-341.
33. Moriarty D, Goldhill J, Selve N, O'Donoghue DP, Baird AW. Human colonic anti-secretory activity of the potent NK(1) antagonist, SR140333: assessment of potential anti-diarrhoeal activity in food allergy and inflammatory bowel disease. Br J Pharmacol 2001; 133: 1346-1354.
34. Mukerji I, Ramkissoon SH, Reddy KK, Rameshwar P. Autocrine proliferation of neuroblastoma cells is partly mediated through neurokinin receptors: relevance to bone marrow metastasis. J Neurooncol 2005; 71: 91-98.
35. Munoz M, Rosso M, Covenas R, Soult JA. Antitumoral action of neurokinina-1 receptor antagonists in human brain cancer cell lines. In: Young AV (ed.). Brain Cancer: Therapy and Surgical Interventions. Nova Science Publishers Inc. 2006; Chapter III. pp. 1-32.
36. Munoz M, Rosso M, Perez A, Covenas R, Rosso R, Zamarriego C, Piruat JI. The NKI receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 2005; 39: 427-432.
37. Munoz M, Rosso M, Perez A, Covenas R, Rosso R, Zamarriego C, Soult JA, Montero I. Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci 2005; 46: 2567-2570.
38. Murai M, Morimoto H, Maeda Y, Fujii T. Effects of the tripeptide substance P antagonist, FR113680, on airway constriction and airway edema induced by neurokinins in guinea-pigs. Eur J Pharmacol 1992; 217: 23-29.
39. Musazzi L, Perez J, Hunt SP, Racagni G, Popoli M. Changes in signaling pathways regulating neuroplasticity induced by neurokinin 1 receptor knockout. Eur J Neurosci 2005; 21: 1370-1378.
40. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med 1999; 340: 190-195.
41. Osorio-Sanchez JA, Karapetis C, Koczwara B. Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting. Intern Med J 2007; 37: 247-250.
42. Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev 1993; 73: 229-308.
43. Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi CA, Manzini S. Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer 2000; 82: 480-487.
44. Palma C, Goso C, Manzini S. Different susceptibility to neurokinin 1 receptor antagonists of substance P and septide-induced interleukin-6 release from U373 MG human astrocytoma cell line. Neurosci Lett 1994; 171: 221-224.
45. Palma C, Maggi CA. The role of tachykinins via NK1 receptors in progression of human gliomas. Life Sci 2000; 67: 985-1001.
46. Palma C, Nardelli F, Manzini S. Correlation between binding characteristics and functional antagonism in human glioma cells by tachykinin NK1 receptor antagonists. Eur J Pharmacol 1999; 374: 435-443.
47. Palma C, Nardelli F, Manzini S, Maggi CA. Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors. Br J Cancer 1999; 79: 236-243.
48. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. Tachykinins and tachykinin receptors: a growing family. Life Sci 2004; 74: 1445-1463.
49. Pinto FM, Almeida TA, Hernandez M, Devillier P, Advenier C, Candenas ML. mRNA expression of tachykinins and tachykinin receptors in different human tissues. Eur J Pharmacol 2004; 494: 233-239.
50. Quartara L, Maggi CA. The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles. Neuropeptides 1998; 32: 1-49.
51. Reinke EK, Johnson MJ, Ling C, Karman J, Lee J, Weinstock JV, Sandor M, Fabry Z. Substance P receptor mediated maintenance of chronic inflammation in EAE. J Neuroimmunol 2006; 180: 117-125.
52. Saria A. The tachykinin NK1 receptor in the brain: pharmacology and putative functions. Eur J Pharmacol 1999; 375: 51-60.
53. Schaffer S, Takahashi K, Azuma J. Role of osmoregulation in the actions of taurine. Amino Acids 2000; 19: 527-546.
54. Schulz S, Stumm R, Rocken C, Mawrin C, Schulz S. Immunolocalization of full-length NK1 tachykinin receptors in human tumors. J Histochem Cytochem 2006; 54: 1015-1020.
55. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. The tachykinin peptide family. Pharmacol Rev 2002; 54: 285-322.
56. Singh AS, Caplan A, Corcoran KE, Fernandez JS, Preziosi M, Rameshwar P. Oncogenic and metastatic properties of preprotachykinin-I and neurokinin-1 genes. Vascul Pharmacol 2006; 45: 235-242.
57. Song H, Moon A. Glial cell-derived neurotrophic factor (GDNF) promotes low-grade Hs683 glioma cell migration through JNK, ERK-1/2 and p38 MAPK signaling pathways. Neurosci Res 2006; 56: 29-38.
58. Tchoumkeu-Nzouessa GC, Rebel G. Characterization of taurine transport in human glioma GL15 cell line: regulation by protein kinase C. Neuropharmacology 1996; 35: 37-44.
59. Torrens Y, Daguet De Montety MC, el Etr M, Beaujouan JC, Glowinski J. Tachykinin receptors of the NK1 type (substance P) coupled positively to phospholipase C on cortical astrocytes from the newborn mouse in primary culture. J Neurochem 1989; 52: 1913-1918.
60. Tsao P, Cao T, von Zastrow M. Role of endocytosis in mediating downregulation of C protein-coupled receptors. Trends Pharmacol Sci 2001; 22: 91-96.
61. Valter MM, Wiestler OD, Pietsche T. Differential control of VEGF synthesis and secretion in human glioma cells by IL-1 and EGF. Int J Dev Neurosci 1999; 17: 565-577.
62. Wiesenhofer B, Stockhammer G, Kostron H, Maier H, Hinterhuber H, Humpel C. Glial cell line-derived neurotrophic factor (GDNF) and its receptor (GFR-alpha 1) are strongly expressed in human gliomas. Acta Neuropathol (Berl) 2000; 99: 131-137.
63. Williams R, Zou X, Hoyle GW. Tachykinin-1 receptor stimulates proinflammatory gene expression in lung epithelial cells through activation of NF-kappaB via a G(q)-dependent pathway. Am J Physiol Lung Cell Mol Physiol 2007; 292: L430-L437.
64. Yamaguchi K, Richardson MD, Bigner DD, Kwatra MM. Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCdelta. Cancer Chemother Pharmacol 2005; 56: 585-593.
65. Zimmer G, Rohn M, McGregor GP, Schemann M, Conzelmann KK, Herrler G. Virokinin, a bioactive peptide of the tachykinin family, is released from the fusion protein of bovine respiratory syncytial virus. J Biol Chem 2003; 278: 46854-46861.